and albumins which derive from human blood plasma. Biotest also develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest currently employs more than 2,500 people worldwide.

The most important raw material for their pharmaceuticals is human blood plasma, which they process into effective and highly purified drugs in one of their world leading fractionation facilities in Europe. These medications are used to treat life-threatening diseases such as blood coagulation disorders (haemophilia), severe infections and immune system disorders.